HemoGenix^®

• Home
• About Us
• Special Offers
• Webinars
• Downloads
• Contact Us

• Applications
  • In Vitro Stem Cell Hemotoxicity Testing
    • Hemotoxicity Testing in Drug Discovery and Development
    • Hemotoxicity Testing for Environmental Agents
    • Hemotoxicity Testing in Research and Other Fields
    • The Importance of Stem Cell Toxicity Testing
    • The HemoGenix^® Concept of Hemotoxicity Testing
    • Predictive In Vitro Hemotoxicity Testing Using HALO^®
    • HALO^® Platform for Hemotoxicity and Drug Interaction Testing
    • HALO^® and Multiparameter Testing
    • Mechanism of Action - Apoptosis and Oxidative DNA Damage

In 2005, the HemoGenix^® article entitled "Validation and Development of a Predictive Paradigm for Hemotoxicology Using a Multifunctional Bioluminescence Colony-Forming Proliferation Assay" was published in Toxicological Sciences (Vol. 87, Pages 427-441). This research article describes how the HALO^® Platform was validated as a cytotoxicity assay against the Registry of Cytotoxicity (RC) Prediction Model published by the NIH in 2001 with the title "Guidance Document on Using In Vitro Data to Estimate in vivo starting doses for Acute Toxicity" (No.: 01-4500.

URL: http://iccvam.niehs.nih.gov/methods/invidocs/guidance/iv_guide.htm.

The RC Prediction Model allows a validated cytotoxicity assay to be used to convert inhibitory concentrations (IC values) into in vivo relevant doses for animal studies. In our Toxicological Sciences article, we have gone one step further and demonstrated that when HALO^® is used with fresh human target cells, the IC results can be converted to human dosing values in mg/kg or mg/m². For the drugs tested, almost all produced comparable values to those that are actually being used today in anti-cancer clinical therapy. As far as we are aware, no other in vitro assay system has been taken to this extreme and demonstrated that it can predict dosing for human clinical trials.

It is for this reason why we can call the HALO^® Platform a true Predictive Hemotoxicity Assay and why it should be used at the earliest possible stage in drug discovery and development.

To be able to use HALO^® for Predictive Hemotoxicology, we have developed several specialized assays that allow a "global" view of the lympho-hematopoietic system to be assessed and to determine potential residual drug damage and change in drug sensitivity to multiple administrations. Our goal is to provide you, the user, with the best possible tools to determine lympho-hemotoxicity. As such, we are continually striving to produce new, validated assays.

The latest predictive hemotoxicity platform to be developed by HemoGenix^® is HALO^®-DDI (Drug-Drug Interaction). This powerful, cell-based is used to study the effect of combining two or more compounds on the response of the cells of the lympho-hematopoietic system.